University of Zurich

uzh.ch

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

1,040

Active

120

Phase 3

42

Total enrollment

624,148

Pipeline matrix

Showing 20 of 20 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Bryophyllum————2
Supplemental oxygen therapy—————1
Oxygen————5
Temozolomide—————2
Ruxolitinib Topical Cream—————1
Propranolol—————1
ALUTARD SQ® Felis domesticus—————1
Pembrolizumab—————1
Tideglusib—————1
Vortioxetine—————1
50% N2O plus 50% O2—————1
Control Group—————1
Gabapentin—————1
Sulfasalazine—————1
Memantine—————1
Sevoflurane——9
intrathecal nivolumab and intrathecal ipilimumab—————1
Intranasal ketamine hydrochloride—————1
Fecal Microbiota Transplantation—————1
¹⁸F-florbetaben—————1

Next readouts

  • 2025-12
  • 2025-12
  • 2025-12-01
  • 2026-04-22
  • 2026-04-30
  • 2026-06
  • 2026-07-31
  • 2026-09-30
  • 2027-02
  • 2027-05-31

Top conditions

  • Healthy31
  • Pulmonary Hypertension24
  • Stroke17
  • High Altitude Pulmonary Hypertension16
  • Chronic Obstructive Pulmonary Disease16
  • Glaucoma14
  • Spinal Cord Injury11
  • Coronary Artery Disease10

Frequently asked questions about University of Zurich

How many clinical trials does University of Zurich have on ClinicalTrials.gov?
University of Zurich is listed as the lead sponsor on 1,040 clinical trials in ClinicalTrials.gov, 120 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Zurich's trials are in Phase 3?
42 of University of Zurich's trials are in Phase 3, spread across 20 active drug programs.
What therapeutic areas does University of Zurich focus on?
University of Zurich's most-studied conditions on ClinicalTrials.gov are Healthy, Pulmonary Hypertension, Stroke, High Altitude Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease.
When are University of Zurich's next clinical trial readouts?
University of Zurich has 10 upcoming primary-completion readouts tracked here; the soonest is “Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients”, expected around 2025-12.